Open Accessibility Menu

Myeloma Cancer Trials


54767414SMM3001 – A phase III randomized, multicenter study of subcutaneous daratumumab versus active monitoring in subjects with high-risk smoldering multiple myeloma.

  1. What type of cancer? What stage?
    1. Smoldering multiple myeloma.
  2. Who is eligible?
    1. Diagnosed within 5 years.
  3. How will I be treated?
    1. Daratumumab – an antibody-based drug, directed against CD38.

For physicians: more information about this specific trial at

Related locations